Viracta Therapeutics, Inc.
(NASDAQ : SNSS)

( )
SNSS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 6.42%282.350.0%$4047.51m
BNTXBioNTech SE 8.17%302.690.0%$1321.33m
NVAXNovavax, Inc. 28.90%182.8578.2%$874.24m
AMGNAmgen, Inc. 1.21%211.321.4%$643.80m
GILDGilead Sciences, Inc. 0.22%69.651.0%$510.30m
LGVNLongeveron Inc. -3.31%19.580.0%$453.36m
VRTXVertex Pharmaceuticals, Inc. 0.08%205.221.9%$451.66m
REGNRegeneron Pharmaceuticals, Inc. 1.61%635.092.7%$406.05m
ILMNIllumina, Inc. 5.06%369.433.3%$341.03m
SNSSSunesis Pharmaceuticals, Inc. 2.38%4.310.7%$301.28m
BIIBBiogen, Inc. 1.21%226.831.8%$284.75m
SGENSeagen Inc. 0.30%146.445.8%$152.49m
INCYIncyte Corp. 2.65%66.732.4%$150.12m
EXASEXACT Sciences Corp. 3.12%83.3618.0%$145.51m
BMRNBioMarin Pharmaceutical, Inc. 2.23%86.124.2%$137.03m

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.